<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04669041</url>
  </required_header>
  <id_info>
    <org_study_id>LPS16135</org_study_id>
    <secondary_id>U1111-1227-3920</secondary_id>
    <nct_id>NCT04669041</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Efficacy and the Safety of Single Pill Combination (SPC) Ezetimibe/Rosuvastatin in Chinese Adult Patients With Primary Hypercholesterolemia Not Adequately Controlled on Statin Therapy</brief_title>
  <acronym>ROZEL</acronym>
  <official_title>A Randomized Double-blinded, Double Dummy, Active-controlled, Parallel Design, Phase 3 Clinical Trial to Evaluate the Efficacy and the Safety of Single Pill Combination (SPC) Ezetimibe/Rosuvastatin in Chinese Adult Patients With Primary Hypercholesterolemia, Not Adequately Controlled on Statin Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:&#xD;
&#xD;
      To demonstrate the superiority of the single pill combination (SPC) ezetimibe 10&#xD;
      mg/rosuvastatin 10 mg (E10/R10) compared to rosuvastatin 10 mg (R10), in the reduction of low&#xD;
      density lipoprotein cholesterol (LDL-C) after 8 weeks.&#xD;
&#xD;
      Secondary Objectives:&#xD;
&#xD;
        -  To evaluate the proportion of patients who attain their LDL-C goal.&#xD;
&#xD;
        -  To evaluate the effect of SPC (E10/R10) compared to rosuvastatin 10 mg (R10) in&#xD;
           reduction of LDL-C at Week 4.&#xD;
&#xD;
        -  To evaluate the effect of SPC (E10/R10) compared to R10 on other lipid parameters at&#xD;
           Week 4 and Week 8.&#xD;
&#xD;
        -  To evaluate the safety of SPC (E10/R10) and R10.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study duration per participants is approximatively 16 weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 8, 2020</start_date>
  <completion_date type="Anticipated">March 2022</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent change in measured LDL-C from baseline (the last available measured LDL-C value obtained up to randomization) to Week 8</measure>
    <time_frame>Baseline to Week 8</time_frame>
    <description>The percent change from baseline in measured LDL-C at Week 8 will be analyzed in the modified intent-to-treat (mITT) population using a mixed effect model with repeated measures (MMRM) approach.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients who attain lipid goal (measured LDL-C &lt;2.6 mmol/L [100 mg/dL]) at Week 8</measure>
    <time_frame>Week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change in measured LDL-C plasma level from baseline to Week 4</measure>
    <time_frame>Baseline to Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change in total cholesterol (TC) from baseline to Week 8</measure>
    <time_frame>Baseline to Week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change in TC from baseline to Week 4</measure>
    <time_frame>Baseline to Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change in triglyceride (TG) serum levels from baseline to Week 8</measure>
    <time_frame>Baseline to Week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change in TG serum levels from baseline to Week 4</measure>
    <time_frame>Baseline to Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change in high density lipoprotein cholesterol (HDL-C) from baseline to Week 8</measure>
    <time_frame>Baseline to Week 8</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change in HDL-C from baseline to Week 4</measure>
    <time_frame>Baseline to Week 4</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse events (AEs)</measure>
    <time_frame>Up to 16 weeks (±3 days)</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">296</enrollment>
  <condition>Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>Single pill combination (SPC)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Once daily rosuvastatin 10 mg for 4 weeks, then once daily SPC ezetimibe 10 mg /rosuvastatin 10 mg (E10/R10) for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rosuvastatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Once daily rosuvastatin 10 mg for 4 weeks, then once daily rosuvastatin 10 mg (R10) for 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin</intervention_name>
    <description>Pharmaceutical form:Tablet Route of administration: Oral</description>
    <arm_group_label>Rosuvastatin</arm_group_label>
    <arm_group_label>Single pill combination (SPC)</arm_group_label>
    <other_name>Crestor®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SPC ezetimibe/rosuvastatin</intervention_name>
    <description>Pharmaceutical form:Tablet Route of administration: Oral</description>
    <arm_group_label>Single pill combination (SPC)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosuvastatin active capsule</intervention_name>
    <description>Pharmaceutical form:Capsule Route of administration: Oral</description>
    <arm_group_label>Rosuvastatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Pharmaceutical form:Tablet Route of administration: Oral</description>
    <arm_group_label>Rosuvastatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Pharmaceutical form:Capsule Route of administration: Oral</description>
    <arm_group_label>Single pill combination (SPC)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria :&#xD;
&#xD;
          -  Participant must be at least 18 years of age inclusive, at the time of signing the&#xD;
             informed consent.&#xD;
&#xD;
          -  Patients with primary hypercholesterolemia.&#xD;
&#xD;
          -  Inclusion criteria in the run-in period: Participants who are not adequately&#xD;
             controlled (defined by screening LDL-C &gt;2.6 mmol/L (100 mg/dL) and ≤4.9 mmol/L (190&#xD;
             mg/dL)with a 10 mg stable daily dose of rosuvastatin, or equipotent statin for 4 weeks&#xD;
             prior to the screening visit, without any other lipid modifying therapy (LMT).&#xD;
             Inclusion criteria in the randomized double-blind period: Participants who are not&#xD;
             adequately controlled based on sample taken at qualifying pre randomization visit,&#xD;
             despite stabilized dose of rosuvastatin 10 mg (defined by measured LDL-C ≥2.6 mmol/L&#xD;
             (100 mg/dL) and ≤4.9 mmol/L (190 mg/dL).&#xD;
&#xD;
          -  Contraceptive use by men or women should be consistent with local regulations&#xD;
             regarding the methods of contraception for those participating in clinical studies.&#xD;
&#xD;
          -  Capable of giving signed informed consent.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Homozygous familial hypercholesterolemia (FH) (clinically or previous genotyping).&#xD;
&#xD;
          -  Patient who has received LDL-C plasmapheresis treatment within 2 months prior to the&#xD;
             screening visit, or has plans to receive it during the study.&#xD;
&#xD;
          -  Recently diagnosed (within 3 months prior to the screening visit) myocardial&#xD;
             infarction (MI), unstable angina, myocardial revascularization (percutaneous coronary&#xD;
             intervention [PCI], coronary artery bypass graft surgery [CABG]), transient ischemic&#xD;
             attack (TIA), or stroke, carotid revascularization, endovascular procedure or surgical&#xD;
             intervention for peripheral vascular disease.&#xD;
&#xD;
          -  Planned to undergo scheduled PCI, CABG, carotid or peripheral revascularization during&#xD;
             the study.&#xD;
&#xD;
          -  Severe hypertension (treated or untreated) with systolic blood pressure (SBP) &gt;160 mm&#xD;
             Hg or diastolic blood pressure (DBP) &gt;100 mm Hg at study entry.&#xD;
&#xD;
          -  History of severe congestive heart failure (New York Heart Association Class IIIb or&#xD;
             IV) within the past 12 months.&#xD;
&#xD;
          -  Presence of any clinically significant uncontrolled endocrine disease known to&#xD;
             influence serum lipids or lipoproteins, according to Investigator's medical judgement.&#xD;
&#xD;
          -  Uncontrolled (as determined by fasting glucose &gt;180 mg/mL or HbA1c &gt;9%) or newly&#xD;
             diagnosed (within 3 months of study entry) diabetes mellitus at the screening visit.&#xD;
&#xD;
          -  History of cancer within the past 5 years, except for adequately treated basal cell or&#xD;
             squamous cell skin cancer, or in situ cervical cancer.&#xD;
&#xD;
          -  Conditions/situations such as:&#xD;
&#xD;
               -  Patient with a short life expectancy.&#xD;
&#xD;
               -  Patient with conditions/concomitant diseases making them non-evaluable for the&#xD;
                  primary efficacy endpoint, according to Investigator's medical judgement.&#xD;
&#xD;
               -  Requirement for concomitant treatment that could bias primary evaluation,&#xD;
                  according to Investigator's medical judgement.&#xD;
&#xD;
               -  Impossibility to meet specific protocol requirements (eg, ability to make study&#xD;
                  visits).&#xD;
&#xD;
               -  Patient is the Investigator or any Sub-Investigator, research assistant,&#xD;
                  pharmacist, study coordinator, other study staff or relative thereof directly&#xD;
                  involved in the conduct of the study.&#xD;
&#xD;
               -  Patient not suitable for participation, whatever the reason, as judged by the&#xD;
                  Investigator, including medical or clinical conditions, or patients potentially&#xD;
                  at risk of noncompliance to study procedures.&#xD;
&#xD;
          -  Known history of hypersensitivity reaction to statins and/or ezetimibe.&#xD;
&#xD;
          -  Current myopathy.&#xD;
&#xD;
          -  A history of statin-induced myopathy or rhabdomyolysis.&#xD;
&#xD;
          -  Current active liver disease including unexplained, persistent elevations of serum&#xD;
             transaminases and any serum transaminase elevation exceeding 3 x upper limit of normal&#xD;
             (ULN) range at the screening visit.&#xD;
&#xD;
          -  All contraindications to the active comparator (rosuvastatin) and background therapies&#xD;
             or warning/precaution of use (when appropriate) as displayed in the respective&#xD;
             National Product Labeling.&#xD;
&#xD;
          -  Patients not previously instructed on a cholesterol-lowering diet prior to the&#xD;
             screening visit.&#xD;
&#xD;
          -  Use of systemic corticosteroids, unless used as replacement therapy for&#xD;
             pituitary/adrenal disease with a stable regimen for at least 6 weeks prior to&#xD;
             screening visit.&#xD;
&#xD;
          -  Use of hormone replacement therapy or oral contraceptives unless regimen has been&#xD;
             stable in the past 6 weeks prior to the screening visit and no plans to change the&#xD;
             regimen during the study.&#xD;
&#xD;
          -  Concomitant administration of cyclosporine (at screening and randomization visits).&#xD;
&#xD;
          -  Human immunodeficiency virus (HIV) patients receiving protease inhibitors (at&#xD;
             screening and randomization visits).&#xD;
&#xD;
          -  Patient who has taken any active investigational drugs (E10/R10) within 1 month or 5&#xD;
             half-lives prior to screening, whichever is longer.&#xD;
&#xD;
          -  Laboratory findings obtained during the screening visit (V1):&#xD;
&#xD;
               -  Fasting serum TGs &gt;400 mg/dL.&#xD;
&#xD;
               -  Positive serum pregnancy test.&#xD;
&#xD;
               -  Serum creatine kinase &gt;3 times ULN.&#xD;
&#xD;
               -  Thyroid-stimulating hormone (TSH) &lt; lower limit of normal (LLN) or &gt; ULN.&#xD;
&#xD;
               -  Glycated hemoglobin A1c (HbA1c) &gt;9%.&#xD;
&#xD;
               -  Estimated glomerular filtration rate &lt;30 mL/min/1.73 m2.&#xD;
&#xD;
               -  Alanine aminotransferase or AST &gt;3 x ULN.&#xD;
&#xD;
          -  Individuals accommodated in an institution because of regulatory or legal order;&#xD;
             prisoners or subjects who are legally institutionalized.&#xD;
&#xD;
          -  Any technical/administrative reason (eg, patient homeless) that makes it impossible to&#xD;
             enroll/randomize the patient in the study.&#xD;
&#xD;
          -  Alcohol abuse according to Investigator's medical judgement.&#xD;
&#xD;
          -  Participants are dependent on the Sponsor or Investigator (in conjunction with Section&#xD;
             1.61 of the ICH-GCP Ordinance E6).&#xD;
&#xD;
          -  Participants are employees of the clinical study site or other individuals directly&#xD;
             involved in the conduct of the study, or immediate family members of such individuals.&#xD;
&#xD;
          -  Any specific situation during study implementation/course that may rise ethics&#xD;
             considerations.&#xD;
&#xD;
          -  Sensitivity to any of the study interventions, or components thereof, or drug or other&#xD;
             allergy that, in the opinion of the Investigator, contraindicates participation in the&#xD;
             study.&#xD;
&#xD;
        The above information is not intended to contain all considerations relevant to a patient's&#xD;
        potential participation in a clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Trial Transparency email recommended (Toll free number for US &amp; Canada)</last_name>
    <phone>800-633-1610</phone>
    <phone_ext>option 6</phone_ext>
    <email>Contact-US@sanofi.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Investigational Site Number 1560052</name>
      <address>
        <city>Changsha</city>
        <zip>410013</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1560020</name>
      <address>
        <city>Jinan</city>
        <zip>250013</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1560027</name>
      <address>
        <city>Shanghai</city>
        <zip>200120</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1560010</name>
      <address>
        <city>Siping</city>
        <zip>136000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1560053</name>
      <address>
        <city>Tianjin</city>
        <zip>300140</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1560047</name>
      <address>
        <city>Wuhan</city>
        <zip>430022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1560009</name>
      <address>
        <city>Wuhan</city>
        <zip>430033</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1560035</name>
      <address>
        <city>Wuhan</city>
        <zip>430080</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1560003</name>
      <address>
        <city>Xuzhou</city>
        <zip>221002</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1560062</name>
      <address>
        <city>Yuncheng</city>
        <zip>044000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1560005</name>
      <address>
        <city>Zhanjiang</city>
        <zip>524001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number 1560011</name>
      <address>
        <city>Zhenjiang</city>
        <zip>212001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>December 8, 2020</study_first_submitted>
  <study_first_submitted_qc>December 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 16, 2020</study_first_posted>
  <last_update_submitted>March 4, 2021</last_update_submitted>
  <last_update_submitted_qc>March 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosuvastatin Calcium</mesh_term>
    <mesh_term>Ezetimibe</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://www.clinicalstudydatarequest.com/</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

